- Home
- LSB vs GRCE Comparison
LSB vs GRCE Comparison
Compare LSB & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- GRCE
- Stock Information
- Founded
- LSB 2002
- GRCE 2002
- Country
- LSB China
- GRCE United States
- Employees
- LSB N/A
- GRCE N/A
- Industry
- LSB
- GRCE
- Sector
- LSB
- GRCE
- Exchange
- LSB NYSE
- GRCE NYSE
- Market Cap
- LSB 31.5M
- GRCE 32.1M
- IPO Year
- LSB N/A
- GRCE N/A
- Fundamental
- Price
- LSB $1.14
- GRCE $2.72
- Analyst Decision
- LSB
- GRCE Strong Buy
- Analyst Count
- LSB 0
- GRCE 1
- Target Price
- LSB N/A
- GRCE $12.00
- AVG Volume (30 Days)
- LSB 17.6K
- GRCE 27.2K
- Earning Date
- LSB 06-21-2025
- GRCE 05-19-2025
- Dividend Yield
- LSB N/A
- GRCE N/A
- EPS Growth
- LSB N/A
- GRCE N/A
- EPS
- LSB N/A
- GRCE N/A
- Revenue
- LSB $79,415,311.00
- GRCE N/A
- Revenue This Year
- LSB $39.33
- GRCE N/A
- Revenue Next Year
- LSB $75.61
- GRCE N/A
- P/E Ratio
- LSB N/A
- GRCE N/A
- Revenue Growth
- LSB N/A
- GRCE N/A
- 52 Week Low
- LSB $1.15
- GRCE $1.75
- 52 Week High
- LSB $11.20
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- LSB 28.76
- GRCE N/A
- Support Level
- LSB $1.16
- GRCE N/A
- Resistance Level
- LSB $1.28
- GRCE N/A
- Average True Range (ATR)
- LSB 0.09
- GRCE 0.00
- MACD
- LSB 0.02
- GRCE 0.00
- Stochastic Oscillator
- LSB 0.00
- GRCE 0.00
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.